Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population

• DOI: 10.3389/fpubh.2022.834744
• Publication Date: 2022-03-14T08:54:47Z
• Authors: María Elena Camac...; Ana María Salinas...; Benjamín Tovar Ci...; Juan Ignacio Garc...; Gloria Navarrete ...; Mario Bermúdez de...
• Keywords: Adult; systemic effects; COVID-19 Vaccines; Adolescent; Population; Social Sciences; Logistic regression; Comorbidity; Infectious disease (medical specialty); Coronavirus Disease 2019 Research; FOS: Health sciences; Coronavirus Disease 2019; 03 medical and health sciences; Sociology; Health Sciences; Humans; Confounding; Disease; Mexico; Internal medicine; BNT162 Vaccine; Demography; local effects; Vaccines; 0303 health sciences; Ad26COVS1; SARS-CoV-2; COVID-19; Odds ratio; Middle Aged; vaccination; FOS: Sociology; 3. Good health; Coronavirus disease 2019 (COVID-19); side effects; Cross-Sectional Studies; Infectious Diseases; Environmental health; Health; Medicine; Factors Affecting Vaccine Hesitancy and Acceptance; Female; Public Health; Self Report; Public aspects of medicine; RA1-1270

A few studies examined the comparative side effects of Coronavirus Disease-19 (COVID-19) vaccines. We compared extension and severity self-reported seven COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac Life Sciences), Gam-COVID-Vac (Gamaleya's Sputnik V), Ad5-nCoV (CanSinoBIO), Ad26.CoV2.S (Johnson & Johnson/Janssen)] in Mexican population. also evaluated association type vaccine, sex, age, comorbidity, history allergies to extent effects. This was a cross-sectional study carried out online between August 12 September 3, 2021 Mexico. The first inclusion criterion receive vaccine second, being at least 18 years old. survey link distributed via multiple social media platforms. questioned about symptoms based on short-term reported literature. Side effect classified as local, systemic, or both. asked need take medicine, stop activities/miss work, seek medical attention. Then, index constructed responses. Descriptive stepwise multivariate logistic ordinal regression analyses were used calculate odds ratio (OR) 95% CI for each outcome adjusted by potential confounders. mean age 38.9 ± 11.0 ( n = 4,024). Prevalence one varied number doses. At dose 1, with highest rate (85%) followed (80%). Both associated greater (adjusted OR 2.53, 2.16, 2.96 2.41, 1.76, 3.29, respectively) 4.32, 3.73, 5.00 3.00, 2.28, 3.94, respectively). Young (<50 years), female severity, independent 2, (88%) only 2.88, 1.59, 5.21) 3.14, 1.82, 5.43). Continuous are necessary acknowledge more post-vaccine different populations.